Related Experiment Video
Updated: Feb 17, 2026
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies
1Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN.
Abstract:
Considerable progress has been made in the treatment of multiple myeloma in the past decade with median survival for the disease improving significantly. This has come through a combination of better understanding of the disease biology and coordinated research into new treatment approaches including better supportive care. However, patients eventually become refractory to available treatments and succumb to the disease, highlighting the need to develop new treatment approaches. The genetic heterogeneity in the disease and clonal evolution under treatment pressure underlie the development of resistance, underscoring the need to develop more effective therapies that can eradicate the disease at initial treatment as well as the need for new classes of drugs with varying mechanisms of action. To this end, there has been intense focus on exploring novel approaches to therapy including small-molecule inhibitors targeting specific abnormalities, immune therapies including monoclonal antibodies and adaptive T-cell therapy, as well as epigenetic approaches. Although many of these drugs are in the early stages of clinical development, the early data appear to be very promising. Many of these drugs can be safely and effectively combined with the current treatment classes such as proteasome inhibitors and immunomodulatory drugs, further enhancing the treatment options for myeloma.
Insights
Advances in multiple myeloma treatment have improved survival, but drug resistance necessitates novel therapies. New approaches like targeted inhibitors and immunotherapies show promise for overcoming treatment resistance in multiple myeloma.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma treatment has seen significant survival improvements over the last decade.
- Understanding disease biology and supportive care have driven progress.
- However, treatment resistance remains a major challenge, necessitating new therapeutic strategies.
Purpose of the Study:
- To review recent advancements in multiple myeloma treatment.
- To highlight the need for novel therapies to overcome drug resistance.
- To discuss emerging treatment modalities and their potential.
Main Methods:
- Review of current literature on multiple myeloma treatment.
- Analysis of novel therapeutic approaches including small-molecule inhibitors, immunotherapies, and epigenetic therapies.
- Evaluation of early clinical data for new drug classes.
Main Results:
- Median survival for multiple myeloma patients has significantly improved.
- Genetic heterogeneity and clonal evolution contribute to treatment resistance.
- Novel therapies including targeted inhibitors and immunotherapies show promising early results.
- New agents can be safely combined with existing treatments like proteasome inhibitors and immunomodulatory drugs.
Conclusions:
- Despite progress, developing therapies to eradicate refractory multiple myeloma is crucial.
- Novel agents targeting specific abnormalities offer new hope.
- Combination therapies hold potential for enhanced treatment outcomes in multiple myeloma.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle
02:17The Tumor Microenvironment